CA2244418C - Procede d'embolisation de vaisseaux sanguins - Google Patents

Procede d'embolisation de vaisseaux sanguins Download PDF

Info

Publication number: CA2244418C
Authority: CA; Canada
Prior art keywords: polymer; biocompatible; blood; composition; agent
Prior art date: 1996-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002244418A

Other languages

English (en)

Other versions

CA2244418A1 (fr

Inventor

Scott Evans

John Ii Perl

Richard J. Greff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Covidien LP

Original Assignee

Micro Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-31

Filing date

1997-01-27

Publication date

2006-03-21

1996-01-31 Priority claimed from US08/594,574 external-priority patent/US5702361A/en

1997-01-27 Application filed by Micro Therapeutics Inc filed Critical Micro Therapeutics Inc

1997-08-07 Publication of CA2244418A1 publication Critical patent/CA2244418A1/fr

2006-03-21 Application granted granted Critical

2006-03-21 Publication of CA2244418C publication Critical patent/CA2244418C/fr

2017-01-27 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

210000004204 blood vessel Anatomy 0.000 title claims description 34
238000000034 method Methods 0.000 title abstract description 39
239000000203 mixture Substances 0.000 claims abstract description 127
229920000642 polymer Polymers 0.000 claims abstract description 92
239000003795 chemical substances by application Substances 0.000 claims abstract description 76
206010002329 Aneurysm Diseases 0.000 claims abstract description 44
230000002792 vascular Effects 0.000 claims abstract description 44
239000002244 precipitate Substances 0.000 claims abstract description 43
239000002904 solvent Substances 0.000 claims abstract description 43
229920000249 biocompatible polymer Polymers 0.000 claims abstract description 37
239000008280 blood Substances 0.000 claims abstract description 27
210000004369 blood Anatomy 0.000 claims abstract description 27
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 69
239000002872 contrast media Substances 0.000 claims description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 20
239000002245 particle Substances 0.000 claims description 19
229910052715 tantalum Inorganic materials 0.000 claims description 17
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 10
229910052697 platinum Inorganic materials 0.000 claims description 10
238000011065 in-situ storage Methods 0.000 claims description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 claims description 5
229910001936 tantalum oxide Inorganic materials 0.000 claims description 5
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 5
229910052721 tungsten Inorganic materials 0.000 claims description 5
239000010937 tungsten Substances 0.000 claims description 5
230000003073 embolic effect Effects 0.000 abstract description 18
229910052751 metal Inorganic materials 0.000 abstract description 8
239000002184 metal Substances 0.000 abstract description 8
238000001556 precipitation Methods 0.000 abstract description 8
231100000216 vascular lesion Toxicity 0.000 abstract description 3
230000010102 embolization Effects 0.000 description 13
208000007536 Thrombosis Diseases 0.000 description 12
229920000219 Ethylene vinyl alcohol Polymers 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000013508 migration Methods 0.000 description 11
230000005012 migration Effects 0.000 description 11
208000032843 Hemorrhage Diseases 0.000 description 10
230000000740 bleeding effect Effects 0.000 description 10
238000011282 treatment Methods 0.000 description 9
229920001577 copolymer Polymers 0.000 description 8
230000003902 lesion Effects 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
229920001747 Cellulose diacetate Polymers 0.000 description 7
230000017531 blood circulation Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
208000034158 bleeding Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
239000000178 monomer Substances 0.000 description 5
238000012276 Endovascular treatment Methods 0.000 description 4
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
239000005977 Ethylene Substances 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
238000004873 anchoring Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 4
239000004715 ethylene vinyl alcohol Substances 0.000 description 4
238000013467 fragmentation Methods 0.000 description 4
238000006062 fragmentation reaction Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
208000022211 Arteriovenous Malformations Diseases 0.000 description 3
206010003226 Arteriovenous fistula Diseases 0.000 description 3
229920001651 Cyanoacrylate Polymers 0.000 description 3
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000005744 arteriovenous malformation Effects 0.000 description 3
229920002301 cellulose acetate Polymers 0.000 description 3
230000004087 circulation Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000007789 sealing Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229920004934 Dacron® Polymers 0.000 description 2
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
201000008450 Intracranial aneurysm Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical group COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
238000002583 angiography Methods 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
238000002594 fluoroscopy Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
208000030304 gastrointestinal bleeding Diseases 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
230000002885 thrombogenetic effect Effects 0.000 description 2
210000002268 wool Anatomy 0.000 description 2
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920000875 Dissolving pulp Polymers 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
239000004830 Super Glue Substances 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
229920006397 acrylic thermoplastic Polymers 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012282 endovascular technique Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
238000002697 interventional radiology Methods 0.000 description 1
208000001286 intracranial vasospasm Diseases 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
238000007726 management method Methods 0.000 description 1
208000022084 motor paralysis Diseases 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000011368 organic material Substances 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920001692 polycarbonate urethane Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000002601 radiography Methods 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
239000003106 tissue adhesive Substances 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
210000001177 vas deferen Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Materials For Medical Uses (AREA)
Surgical Instruments (AREA)

CA002244418A 1996-01-31 1997-01-27 Procede d'embolisation de vaisseaux sanguins Expired - Fee Related CA2244418C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/594,574 US5702361A (en)	1996-01-31	1996-01-31	Method for embolizing blood vessels
US08/594,574		1996-01-31
PCT/US1997/001076 WO1997027888A1 (fr)	1996-01-31	1997-01-27	Procede d'embolisation de vaisseaux sanguins

Publications (2)

Publication Number	Publication Date
CA2244418A1 CA2244418A1 (fr)	1997-08-07
CA2244418C true CA2244418C (fr)	2006-03-21

Family

ID=36101555

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002244418A Expired - Fee Related CA2244418C (fr)	1996-01-31	1997-01-27	Procede d'embolisation de vaisseaux sanguins

Country Status (1)

Country	Link
CA (1)	CA2244418C (fr)

1997
- 1997-01-27 CA CA002244418A patent/CA2244418C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2244418A1 (fr)	1997-08-07

Legal Events

Date	Code	Title	Description
2002-01-23	EEER	Examination request
2014-03-11	MKLA	Lapsed	Effective date: 20140128

Publication	Publication Date	Title
US5702361A (en)	1997-12-30	Method for embolizing blood vessels
CA2215356C (fr)	2009-08-25	Nouvelles compositions d'embolisation
US5695480A (en)	1997-12-09	Embolizing compositions
US6051607A (en)	2000-04-18	Vascular embolizing compositions comprising ethyl lactate and methods for their use
US6342202B1 (en)	2002-01-29	Compositions for use in embolizing blood vessels
US5830178A (en)	1998-11-03	Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
EP0841854B1 (fr)	2002-04-24	Compositions pour l'embolisation de vaisseaux sanguins
WO1997004813A1 (fr)	1997-02-13	Compositions de diacetate de cellulose permettant l'embolisation de vaisseaux sanguins
CA2469734A1 (fr)	2003-07-24	Techniques d'embolisation de sites anevrismaux utilisant une composition d'embolisation a haute viscosite
EP0923399B1 (fr)	2004-06-16	Ensemble de pieces pour des nouveaux procedes d'embolisation de sites vasculaires a l'aide d'une composition d'embolisation comprenant du dymethylsulfoxyde
EP1061988A1 (fr)	2000-12-27	Procedes d'embolotherapie gynecologique endovasculaire
CA2244418C (fr)	2006-03-21	Procede d'embolisation de vaisseaux sanguins
JP5183157B2 (ja)	2013-04-17	新規な塞栓形成組成物